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INTRODUCTION
Allogeneic bone marrow transplantation (BMT) can be
successfully performed with stem cells from an unrelated
donor when stem cells from an HLA-matched family mem-
ber are not available [1-3]. Compared to BMT using HLA-
identical sibling marrow, BMT using unrelated-donor
(URD) unmanipulated T-cell–replete grafts is associated
with higher rates of graft-versus-host disease (GVHD), graft
failure, and infectious complications leading to substantially
greater transplantation-related mortality. The rate of disease
recurrence following URD BMT may be lower than that of
matched related-donor (MRD) transplantation, however,
perhaps because of the increased incidence of GVHD.
The inﬂuence of donor source on transplantation out-
come is less clear when the marrow has been manipulated to
remove T-cells. Donor marrow T-cell depletion (TCD) has
been demonstrated to decrease the incidence and severity of
GVHD following transplantation of matched sibling grafts,
but it has also been associated with the development of graft
rejection, lymphoproliferative disease, and, most problemat-
ically, disease recurrence [4-7]. The effect of TCD when
used for recipients of URD marrow may differ from its
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ABSTRACT
To assess the effect of related versus unrelated donors on outcomes in patients following T-cell–depleted (TCD)
allogeneic BMT, we compared engraftment, GVHD, relapse rates, and survival in BMT patients who received CD6+
TCD marrow from HLA-matched related donors (MRD) with those in patients who received CD6+ TCD marrow
from unrelated donors (URD). A total of 170 consecutive patients (120 with related donors, 50 with unrelated
donors) were analyzed. The 2 groups were similar in age, sex, prior cytomegalovirus exposure, and stage of disease
at the time of transplantation. GVHD prophylaxis was identical in the 2 groups, with TCD as the only method of
GVHD prophylaxis. The total number of nucleated, CD34+, CD3+, and CD6+ cells infused did not significantly
differ between the 2 groups. The median day to reach 500 × 106 neutrophils/L was 12 days for both related (range,
8-22 days) and unrelated (range, 9-23 days) graft recipients (P = .92). Incidence of grades 2 through 4 acute GVHD
was higher in URD than in MRD recipients (42% versus 20%, P = .004). According to multivariable analysis results,
donor source was the single most important factor influencing GVHD (P = .01). The 2-year estimated risk of
relapse was 45.9% in MRD recipients compared to 25.7% in URD recipients (P = .06). Multivariable analysis
revealed that the 2 most pertinent factors adversely affecting overall survival were advanced disease stage (P = .0002)
and age greater than 50 years (P = .0003) at transplantation. There was no difference in relapse-free survival in URD
and MRD recipients. We conclude that for patients undergoing TCD-BMT, use of unrelated marrow is associated
with a higher risk of GVHD and other transplantation-related complications. However, these adverse events do not
lead to inferior probability of relapse-free survival because they are accompanied by a reduction in relapse rates.
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effect in the related-donor transplantation setting. In this
study, we examined the outcome of 170 patients with
leukemia, myelodysplasia (MDS), or non-Hodgkin’s lym-
phoma (NHL) who underwent TCD-BMT at our institu-
tion and received marrow from a related or an unrelated
donor. We compared engraftment, duration of hospitaliza-
tion, incidence of GVHD, relapse rate, and overall survival
(OS) in the 2 groups.
METHODS
Patient Population
The clinical outcome was assessed in patients with
leukemia, lymphoma, or MDS who underwent CD6+ TCD
allogeneic BMT from January 1994 through December
1999. All patients aged 18 to 60 years with these diagnosed
illnesses were included in this analysis. Transplantation eli-
gibility requirements included Eastern Cooperative Oncology
Group performance status 0-2, absence of active infection at
the time of study entry, and normal or near-normal parame-
ters of organ function. During this period, 120 patients
received transplants with HLA-matched related marrow and
50 patients received matched unrelated marrow. Treatment
protocols were approved by the Human Subjects Protection
Committee of the Dana-Farber Cancer Institute (DFCI).
Written informed consent was obtained in all cases.
Donor Population
Serologic analysis was used to determine that all donors
matched recipients at HLA-A and HLA-B loci; in the
majority of donors, molecular methods were also used to
confirmed the match. Class II typing was performed with
sequence-speciﬁc oligonucleotide probes. Molecular analy-
sis showed that all donors matched recipients at HLA-DR
loci. HLA typing of donors and patients was conﬁrmed at
the histocompatibility labs at DFCI or Brigham and Wom-
en’s Hospital. Unrelated marrow was obtained at a National
Marrow Donor Program (NMDP) or affiliated collection
site and transported to our institution by arrangements
made through the NMDP.
Preparative Regimen
Of the 120 MRD patients, 115 received cyclophos-
phamide 60 mg/kg intravenously (IV) ×2 (days –5, –4) on
2 consecutive days followed by total body irradiation (TBI)
as ablation. TBI was administered at a dose of 1400 (n = 42),
1480 (n = 41), or 1560 (n = 32) cGy given twice daily in equal
fractions on days –3, –2, –1, and day 0. All patients were
treated on a dedicated facility using opposing anterior-
posterior/posterior-anterior ﬁelds at a dose rate of 10 cGy/
minute. Individually designed 1- to 8-inch lead cutouts were
placed anteriorly and posteriorly on the skin of the thorax to
compensate for the increased transmission through the
lungs and to bring the lung dose to the same level as the
other normal tissue doses. Five of the 120 MRD patients
had received prior radiotherapy that precluded TBI; these
patients received a preparative regimen of busulfan and
cyclophosphamide. All 50 URD patients received cyclo-
phosphamide (60 mg/kg IV ×2) on 2 consecutive days fol-
lowed by TBI at a dose of 1400 cGy delivered over 4 days
twice daily. CD6 TCD was the sole method of GVHD pro-
phylaxis. Total lymphoid irradiation (TLI) was administered
before ablation to reduce the risk of rejection of the CD6+-
depleted unrelated marrow in all unrelated recipients and
in 2 patient receiving HLA-matched related nonsibling
marrow. In the first 22 URD transplant recipients, TLI
(750 cGy) was delivered through 5 daily 150 cGy fractions
to complementary mantle (morning) and inverted-Y (after-
noon) ports as previously described [8,9]. When it became
evident that engraftment occurred in all patients receiving
750 cGy TLI, the subsequent group of unrelated marrow
recipients received 450 cGy TLI in 3 fractions [10].
Marrow Processing
Donor bone marrow was harvested on the last day of
TBI administration and transported to the Cell Manipula-
tion Laboratory at DFCI, where it was processed. Mononu-
clear cells were isolated from marrow by Ficoll-Hypaque
centrifugal sedimentation. This product was then depleted
of CD6+ T-cells by complement-mediated antibody lysis
using anti-T12 monoclonal antibody as previously described
[11]. Immunophenotypic analysis of the marrow product
was performed before and after antibody-mediated purging.
Monoclonal antibodies to CD3, CD4, CD6, CD8, CD20
(B-cells), and CD56 (natural killer cells) (Coulter Diagnos-
tics, Hialeah, FL) were employed as previously described
[9]. Following purging and within 24 hours of harvesting in
most cases, marrow-derived mononuclear cells were sus-
pended in 50 mL of medium and infused into the patient
through an indwelling central venous catheter. No patients
received prophylactic immune-suppressive therapy, includ-
ing corticosteroids, methotrexate, or cyclosporine, to pre-
vent development of GVHD.
Supportive Care
All patients were treated in high-efficiency particulate
air (HEPA)-ﬁltered rooms using standard reverse-isolation
procedures. Oral trimethoprim-sulfamethoxazole was
administered to all patients from admission until the devel-
opment of a fever requiring intravenous antibacterial antibi-
otics. Trimethoprim-sulfamethoxazole (or an alternative)
was resumed after discharge to prevent Pneumocystis carinii
infection. Acyclovir was administered for Herpes simplex
and Herpes zoster prophylaxis. Screening for cytomegalo-
virus (CMV) antigenemia was performed weekly when
possible until day +120. Patients with evidence of CMV
antigenemia in their blood received ganciclovir for 4 weeks.
All patients received granulocyte colony-stimulating factor
(G-CSF) posttransplantation, and G-CSF administration
continued until the absolute neutrophil count exceeded
1.0 × 109 cells/L. All patients received prestorage leukore-
duced red blood cells and single-donor pheresed platelets
leukoreduced at the time of collection. All blood compo-
nents were irradiated to prevent transfusion-related GVHD.
Patients were cared for at the inpatient unit at DFCI (until
February 1997) or the DFCI Oncology Unit at Brigham
and Women’s Hospital (March 1997-September 1999).
Patient Evaluation
Data were evaluated as of December 31, 2000. Neu-
trophil engraftment was defined as the first of 2 consecu-
tive days in which the absolute neutrophil count exceeded
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0.5 × 109 cells/L. Platelet engraftment was deﬁned as the ﬁrst
of 7 consecutive days in which the platelet count was greater
than 20 × 109 cells/L independent of transfusion. Acute
GVHD was graded according to established criteria [12].
Remission status was assessed by bone marrow evaluation at
approximately 6 and 12 months post-BMT and then yearly
thereafter or as clinically indicated. Disease relapse was identi-
ﬁed by morphologic evidence of recurrent disease in patients
with acute leukemia and by cytogenetic evidence of recurrent
disease in patients with chronic myelogenous leukemia (CML).
Statistical Considerations
Event-free survival (EFS) was measured from the date of
bone marrow infusion to the ﬁrst evidence of relapse, pro-
gression, or death in remission. Patients were censored at the
date on which they were last seen and reported without dis-
ease and at the ﬁrst evidence of relapse. The effect of donor
lymphocyte infusion is not reﬂected in the EFS analysis. OS
was measured from the date of bone marrow infusion to the
date of death or date last known alive. Engraftment, EFS,
and OS were calculated by the method of Kaplan and Meier
[13]. The log-rank test was used to compare EFS and OS
according to patient characteristics [14]. The Fisher exact
test and the Wilcoxon rank sum test were applied to corre-
late presence of engraftment and grades 2 through 4 acute
GVHD with discrete and continuous clinical variables [15].
Multivariate analyses included fitting a logistic regression
model for the bivariate outcomes and the Cox proportional
hazards regression model for the time-to-event outcomes.
Cumulative incidence curves were compared using the class
of k-sample tests proposed by Gray [16].
RESULTS
Patient Characteristics
The characteristics of all patients are detailed in Table 1.
The median ages of MRD and URD recipients were similar,
43 and 46 years, respectively (P = .70). Fifty-eight percent of
MRD recipients and 60% of URD recipients were male (P =
.87). Fifty-nine percent of all patients were male. Forty-one
percent of MRD recipients were CMV seropositive com-
pared to 35% of URD recipients (P = .49). No differences
were observed in sex, age, or CMV seropositivity of the
donors in the MRD and the URD groups. Disease status at
transplantation was classiﬁed as early in patients with acute
leukemia in first remission, stable-phase CML, or MDS
characterized as refractory anemia or refractory anemia with
ringed sideroblasts and was classiﬁed as advanced in patients
with later-stage leukemia, MDS, or NHL. Fifty-seven per-
cent of MRD patients were classiﬁed as having early disease
compared to 54% of URD patients (P = .87). There was a
greater proportion of patients with the diagnosis of acute
lymphoblastic leukemia (ALL) and a lower proportion with
NHL in the URD group than in the MRD group (P = .03).
The median follow-up period for all patients was 32 months.
TCD Marrow Products
Marrow treatment was performed in the same fashion
for both MRD and URD recipients. The median number
of cells and cell subsets infused is displayed in Table 2. Fol-
lowing isolation of mononuclear cells from donor marrow
by Ficoll-Hypaque sedimentation and CD6+ T-cell deple-
tion, a median of 5.82 × 107 nucleated bone marrow
cells/kg were infused into MRD recipients compared to
5.79 × 107 nucleated bone marrow cells/kg into URD
recipients (P = .73). The numbers of CD34+, CD3+, and
CD6+ cells/kg were also not signiﬁcantly different between
the 2 groups. Among MRD and URD recipients, a median
of 12.9 and 13.8 CD34+ ×105 cells/kg (P = .21), 5.3 and
6.6 CD3+ ×105 cells/kg (P = .25), and 0.95 and 1.30 ×105
CD6+ cells/kg (P = .47) were infused, respectively.
Engraftment
There was only 1 case of primary graft failure; this case
occurred in a woman receiving marrow from her brother.
Table 1. Patient Characteristics
MRD URD
(n = 120) URD (n = 50) P
Age
Median 43 y 46 y
<50 y 91 (75.8%) 36 (72.0%)
>50 y 29 (24.2%) 14 (28.0%) .70
Sex (donor/patient)
Male/male 38 (31.7%) 19 (38.0%)
Male/female 30 (25.0%) 11 (22.0%)
Female/male 32 (26.7%) 11 (22.0%)
Female/female 20 (16.7%) 9 (18.0%) .83
Disease status at BMT
Early 52 (43.3%) 23 (46.0%)
Advanced 68 (56.7%) 27 (54.0%) .87
CMV serostatus (donor/patient)
Negative/negative 53 (45.3%) 18 (36.7%)
Negative/positive 26 (22.2%) 7 (14.3%)
Positive/negative 16 (13.7%) 14 (28.6%)
Positive/positive 22 (18.8%) 10 (10.4%)
Unknown 3 1 .11
Diagnosis
AML 38 (22%) 16 (32%)
ALL 12 (8%) 13 (26%)
CML 22 (13%) 11 (22%)
MDS 15 (9%) 6 (12%)
NHL 33 (19%) 4 (8%) .03
Table 2. Immunophenotypic Analysis of Bone Marrow Product
MRD (Range) URD (Range) P
Total nucleated cells 5.82 × 107/kg (2.13-13.98) 5.79 × 107/kg (2.47-13.43) .73
CD34+ cells 1.29 × 106/kg (0.38-4.35) 1.38 × 106/kg (0.21-3.74) .21
CD3+ cells 5.30 × 105/kg (0.5-67.4) 6.60 × 105/kg (0.9-40.9) .25
CD3+CD6+ cells .95 × 105/kg (0.5-60.9) 1.30 × 105/kg (0.5-26.6) .47
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Neutrophil engraftment occurred in all other patients, with
a median day to reach 500 × 106 neutrophils/L of 12 days
for both related (range, 8-22 days) and unrelated (range,
9-23 days) graft recipients (P = .92) (Figure 1). Two patients,
both recipients of related marrow, experienced late graft
failure at 69 and 79 days posttransplantation. Both patients
underwent reconditioning with antithymocyte globulin and
cyclophosphamide and had successful engraftment with
unmanipulated marrow from their original donors. Platelet
engraftment did not differ between the 2 groups, with a
median time to platelet recovery of 25 days for recipients of
MRD transplants and 24 days for recipients of URD trans-
plants (P = .89). Length of hospital stay was longer for URD
marrow recipients (median, 27 days) than for MRD recipi-
ents (median, 23 days) (P < .0001) (Figure 1B), owing per-
haps to the higher rate of acute GVHD described below.
A multivariable analysis assessing the relationship
between speed of engraftment and pretreatment variables
was performed. Speed of engraftment did not correlate with
donor source, age, sex, disease, disease status at transplanta-
tion, or CMV status, nor did it correlate with the total num-
ber of nucleated cells infused or the number of CD3+ or
CD6+ cells infused. However, multivariable analysis did
indicate that patients undergoing transplantation for early
disease (P = .04) and those receiving related marrow (P <
.001) spent less time in the hospital.
Graft-versus-Host Disease
Of the 170 patients, 45 (27%) developed grade 2, 3, or
4 acute GVHD in the absence of any prophylactic immune-
suppressive medication. The incidence of grades 2 through
4 GVHD was 20% in the MRD recipients and 42% in the
URD recipients (P = .004). A logistic regression model of
166 patients for whom data on all baseline clinical variables
were available indicated that donor source influenced
the risk of GVHD (odds ratio, 0.4; P = .01), whereas
patient/donor age, sex, diagnosis, CMV exposure, and dis-
ease status at transplantation did not have signiﬁcant inﬂu-
ence (Table 3).
In the 126 patients for whom complete immunopheno-
typing data were available, the number of CD3+, CD6+, or
CD34+ cells/kg infused did not inﬂuence the risk of GVHD.
Despite receiving comparable numbers of CD3+ T-cells,
patients with unrelated donors had a significantly higher
incidence of acute GVHD than did patients with related
donors. Of 109 evaluable MRD patients, 21 (19%) had
chronic GVHD compared to 22 (54%) of 41 URD patients
(Fisher exact, P < .001).
Disease Relapse
The 2-year estimated risk of relapse was 45.9% for
MRD recipients compared with 25.7% for URD recipients
(P = .06). Univariate analysis of clinical covariates revealed
that disease status at transplantation (P = .002) was the only
other characteristic signiﬁcantly affecting disease outcome.
The number of CD3+ cells infused did not appear to affect
relapse rate. Multivariable analysis using a logistic regres-
sion model including major covariates indicated that early
disease stage at transplantation (hazard ratio, 0.5; P = .01)
and unrelated marrow source (hazard ratio, 0.7; P = .06)
Figure 1. Comparison of neutrophil engraftment (A) and length of
stay (B). A, Time to reach an ANC > 500 in MRD recipients compared
to URD recipients (P = .92). B, Length of hospital stay for MRD recip-
ients compared to that of URD recipients (P < .0001).
Table 3. Logistic Regression Analysis of Effect of Clinical Variables on
Outcome
Grades
2–4 Day 100 Time to
Clinical Variable GVHD Mortality Relapse OS RFS
Related donor
Hazard ratio 0.4 0.4 2.2 0.6 0.8
P .01 .09 .06 .06 .33
Age >50 y
Hazard ratio 1.0 1.2 1.1 2.3 1.8
P .99 .74 .87 .0003 .01
Male patient
Hazard ratio 1.1 1.3 1.1 0.9 0.9
P .83 .59 .72 .56 .50
Male donor
Hazard ratio 1.1 0.5 1.4 1.0 1.1
P .91 .23 .25 .85 .62
CMV negative/negative
Hazard ratio 0.5 0.6 0.7 0.8 0.7
P .14 .47 .35 .41 .29
Early disease stage
Hazard ratio 1.0 0.4 0.5 0.4 0.4
P .92 .12 .01 .0002 .001
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were associated with a reduced risk of relapse posttransplan-
tation. Among patients with CML, 13 (59%) of 22 MRD
recipients demonstrated molecular, cytogenetic, or hemato-
logic relapse compared with 0 of 11 URD recipients (Fisher
exact, P < .002).
Patient Outcome
Despite the somewhat lower relapse rate in patients
receiving unrelated marrow, estimated 2-year OS was similar
in URD (44.5%) and MRD (46.8%) recipients (Figure 2A).
Similarly, relapse-free survival (RFS) rates at 2 years were
virtually identical, 38.3% and 38.4%, in URD and MRD
recipients, respectively (Figure 2B). The equivalent out-
comes can be attributed to higher nonrelapse mortality rates
and lower relapse rates in the URD recipients (Figure 3).
There was no single specific reason that accounted for
increased transplantation deaths in the URD recipients.
Infection and pneumonitis were the most common causes of
nonrelapse mortality in both groups. However, there was a
higher incidence of Epstein-Barr virus lymphoproliferative
disease (EBV-LPD) in URD recipients (5 of 50, 10%) than
in MRD recipients (1 of 120, 1%, P < .01).
Multivariable analysis using a Cox regression model
including baseline clinical variables from 166 assessable
patients indicated that age >50 years (hazard ratio, 2.3; P =
.0003) and advanced disease (hazard ratio, 2.5; P = .0002) at
transplantation were associated with inferior OS (Table 3).
According to results of this multivariable analysis, use of a
related donor was associated with a trend toward superior
OS (hazard ratio, 0.6; P = .06) but was not associated with
signiﬁcantly superior RFS (hazard ratio, 0.8; P = .33).
When a logistic regression model was applied to data
from patients from whom complete immunophenotyping
data were available, results indicated that the number of
CD3+ T-cells infused did influence outcome. Patients
receiving higher numbers of CD3+ cells had improved sur-
vival compared with those patients receiving lower numbers
of CD3+ T-cells (hazard ratio, 0.3; P = .002). The effect on
survival of the number of CD3+ cells infused is shown in
Figure 4. Because CD3 counts were found not to inﬂuence
relapse rates or GVHD, it appears that a higher number of
infused CD3+ cells was associated with a decrease in nonre-
lapse mortality.
DISCUSSION
Our data indicate that RFS after TCD-BMT is similar
in recipients of related and unrelated grafts. Although RFS
was not inﬂuenced by donor source, reasons for failure of
transplantation did differ between the 2 groups of patients.
Recipients of URD TCD marrow had higher rates of
GVHD and attendant transplantation-related complica-
tions than did recipients of MRD TCD marrow. These
results were counterbalanced by lower rates of disease
relapse in URD marrow recipients than in MRD marrow
recipients. This inverse relationship between GVHD and
relapse is similar to that reported after transplantation of
unmanipulated marrow from related and unrelated donors
[2,6,17]. Although an increased risk of relapse has been
noted after TCD MRD transplantation, this relationship
may not be as pronounced in TCD URD, in which the
allogeneic disparity between donor and host may increase
the graft-versus-leukemia (GVL) effect and compensate for
the depleted T-cells [18,19].
Figure 2. OS and RFS following CD6+ TCD-BMT. Kaplan Meier
estimates for OS (A) and RFS (B) are displayed for MRD and URD
transplant recipients.
Figure 3. Competing causes of treatment failure after TCD-BMT in
MRD and URD recipients. The estimated time to relapse and the non-
relapse mortality rate are contrasted for MRD and URD recipients.
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Early series of URD BMT were associated with out-
comes markedly inferior to those of MRD transplantation
[20]. Improvements in HLA typing through the widespread
use of molecular rather than serologic typing has allowed
identification and selection of donors who are truly
matched at major HLA loci. As a consequence of improved
HLA typing, according to recent study reports, survival
rates after URD BMT are approaching those associated
with MRD BMT [17,21-24]. In the current series of
patients receiving TCD marrow, just such a relationship
was observed between survival rates for URD and MRD
recipients. Advanced age and stage of disease at transplanta-
tion were far more important determinants of ultimate out-
come than was marrow source.
The contrast in the rates of acute and chronic GVHD
between URD and MRD recipients underscores the impor-
tance of minor histocompatibility antigen differences
between patients and donors. All patients included in this
analysis received marrow from donors matched at HLA-A,
-B, and -DR loci. All patients underwent identical forms of
TCD. Radiation doses varied slightly between the 2 patient
populations. All patients receiving URD marrow received
1400 cGy TBI, whereas 62% of patients receiving MRD
marrow received either 1480 cGy or 1560 cGy TBI. This
difference in TBI dose is unlikely to affect relapse rate. We
recently reported a comparison of relapse rates in patients
receiving 1400, 1480, or 1560 cGy TBI in which we found
no signiﬁcant effect of TBI dose on relapse rate [25].
Both the type and number of T-cells infused at the time
of transplantation may affect risk of relapse and GVHD.
CD6 is a narrow-specificity antibody that results in an
approximately 2-log reduction in T-cells [11,26]. This mod-
est reduction in T-cells results in an overall incidence of
grades 2 through 4 GVHD of 20% in related-donor mar-
row recipients, an incidence comparable to that resulting
from other forms of TCD [25,27]. The cumulative early and
late graft-failure rate in using CD6 TCD is low, <3%, and
compares favorably with other forms of TCD in related-
donor transplantation. A recent overview of TCD trans-
plantation demonstrated that TCD using narrow-speciﬁcity
antibodies was associated with improved leukemia-free sur-
vival and less risk of graft rejection than was transplantation
with more extensive, broad-specificity TCD techniques
such as soybean agglutinin [28].
In this study, TCD did increase the risk of EBV-LPD in
patients who underwent URD transplantation. TCD is a
known risk factor for this complication. In addition, the
increased incidence of GVHD noted in patients undergoing
URD transplantation and the need for more intensive
immune-suppressive medications no doubt contributed to
the development of this complication. Early detection of
EBV-LPD and use of agents such as Rituxan may reduce the
signiﬁcance of this complication [29].
There were no signiﬁcant differences between the num-
ber of T-cells infused in patients undergoing MRD trans-
plantation and those undergoing URD transplantation.
Although minor HLA antigens were not measured directly, it
seems clear that they were critical determinants of GVH and
perhaps GVL activity. In the last few years, characterization
of minor HLA antigens has improved our understanding of
GVH and GVL responses [30-32]. Identification of these
structures and their use for donor selection may lead to
reduction of rates of GVHD in URD recipients to those
noted in MRD recipients.
It is interesting that within the range of cells infused,
there was no inﬂuence of T-cell number on the incidence of
GVHD. In addition, no effect on relapse rates was noted.
However, overall outcome was superior in those patients
who received greater numbers of T-cells (independent of
marrow source). It therefore appears that T-cell number
affected nonrelapse mortality. This observation is important
for future TCD trials. Strategies engineered to purge T-cells
exhaustively and arbitrarily from donor marrow may pro-
duce inferior results. Further support for this notion comes
from an extensive International Bone Marrow Transplant
Registry (IBMTR) analysis that demonstrated that the use
of narrow-specificity antibodies produced survival rates
superior to those produced with broad-speciﬁcity antibodies
[28]. We hope to determine at some point the “correct”
dose and type of T-cells that should remain in the donor
marrow to minimize GVHD, preserve GVL, and maintain
immune integrity.
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Figure 4. Effect of the number of infused CD3+ cells on survival. The
inﬂuence of the number of CD3+ cells infused (higher or lower than
median of 5.30 × 105 CD3+ cells/kg) on outcome is compared. Multi-
variable analysis revealed that patients receiving higher numbers of
CD3+ cells had superior survival (hazard ratio, 0.3; P = .002).
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